Article Information
History
- March 27, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Eugene J. Gardner@,1,
- Katherine A. Kentistou1,
- Stasa Stankovic1,
- Samuel Lockhart2,
- Eleanor Wheeler1,
- Felix R. Day1,
- Nicola D. Kerrison1,
- Nicholas J. Wareham1,
- Claudia Langenberg1,4,
- Stephen O’Rahilly*,2,3,
- Ken K. Ong*,1,5 and
- John R. B. Perry*,@,1,6
- 1MRC Epidemiology Unit, Wellcome–MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- 2MRC Metabolic Diseases Unit, Wellcome–MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- 3NIHR Cambridge Biomedical Research Centre, Cambridge, UK
- 4Computational Medicine, Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany
- 5Department of Paediatrics, University of Cambridge, Cambridge, UK
- 6Metabolic Research Laboratory, Wellcome–MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
- ↵@Corresponding authors: eugene.gardner{at}mrc-epid.cam.ac.uk; john.perry{at}mrc-epid.cam.ac.uk
Posted March 27, 2022.
Damaging missense variants in IGF1R implicate a role for IGF-1 resistance in the aetiology of type 2 diabetes
